Pediatrix Medical Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Pediatrix Medical Group heeft een totaal eigen vermogen van $732.5M en een totale schuld van $626.7M, wat de schuld-eigenvermogensverhouding op 85.6% brengt. De totale activa en totale passiva bedragen respectievelijk $2.1B en $1.3B. De EBIT Pediatrix Medical Group is $164.6M waardoor de rentedekking 4.6 is. Het heeft contanten en kortetermijnbeleggingen van $220.5M.
Belangrijke informatie
85.6%
Verhouding schuld/eigen vermogen
US$626.72m
Schuld
| Rente dekkingsratio | 4.6x |
| Contant | US$220.45m |
| Aandelen | US$732.49m |
| Totaal verplichtingen | US$1.34b |
| Totaal activa | US$2.08b |
Recente financiële gezondheidsupdates
Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden
Oct 19
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Recent updates
Pediatrix Medical Group: The Business Is Turning
Nov 18Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth
Nov 06Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden
Oct 19We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
Sep 28Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly
Feb 15Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $528.2M ) MD } overtreffen de korte termijn passiva ( $373.1M ).
Langlopende schulden: De kortetermijnactiva van MD ( $528.2M ) dekken de langetermijnschulden ( $971.3M ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 55.5% ) MD wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van MD is de afgelopen 5 jaar gedaald van 131.1% naar 85.6%.
Schuldendekking: De schuld van MD wordt goed gedekt door de operationele kasstroom ( 22.8% ).
Rentedekking: De rentebetalingen op de schuld van MD worden goed gedekt door EBIT ( 4.6 x dekking).